Literature DB >> 3315981

The immunogenicity of tumour cells.

L K Ashman1.   

Abstract

Immunological mechanisms are demonstrably of central importance in preventing the development of certain virus-associated cancers in animals and man; however, they do not appear to fulfill this role in the majority of 'spontaneous' tumours. This does not, however, necessarily indicate that spontaneous tumours lack potential target antigens for immunologically mediated destruction. Work in the field of transplantation immunology has clearly shown that certain cell types fail to elicit rejection reactions despite their possession of alloantigens. Similarly, some tumour cell types are poorly immunogenic to the point that they can grow in and kill animals despite a major histocompatibility barrier. These tumours are, however, susceptible to destruction in vivo in appropriately allo-sensitized animals. Thus, some tumours may be able to grow in autologous or syngeneic hosts because of their poor immunogenicity, despite the fact that they express potential (tumour-associated) rejection antigens. It may be possible to manipulate this situation for therapeutic purposes.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3315981     DOI: 10.1038/icb.1987.31

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN: 0818-9641            Impact factor:   5.126


  4 in total

1.  Requirements for the stimulation of allogeneic T lymphocytes by acute non-lymphoblastic leukaemia cells.

Authors:  L K Ashman; G W Kriek; S J Cooper; D E O'Keefe
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

2.  HL-60 myeloid leukaemia cells acquire immunostimulatory capability upon treatment with retinoic acid: analysis of the responding population and mechanism of cytotoxic lymphocyte activation.

Authors:  S M Geary; L K Ashman
Journal:  Immunology       Date:  1996-07       Impact factor: 7.397

3.  Ex vivo induction of antitumor DEC-205+ CD11c+ cells in a murine neuroblastoma model by co-stimulation with doxorubicin, lipopolysaccharide and interleukin-4.

Authors:  Seiichiro Inoue; Yumiko Setoyama; Yoshifumi Beck; Daiki Kitagawa; Akio Odaka
Journal:  Biomed Rep       Date:  2015-11-20

4.  Improved Anti-Tumour Adaptive Immunity Can Overcome the Melanoma Immunosuppressive Tumour Microenvironment.

Authors:  Nana Dang; Mark Waer; Ben Sprangers; Yuan Lin
Journal:  Cancers (Basel)       Date:  2019-10-31       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.